The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Eton Pharmaceuticals Inc (NASDAQ: ETON) closed at $18.92 down -5.78% from its previous closing price of $20.08. In other words, the price has decreased by -$5.78 from its previous closing price. On the day, 0.97 million shares were traded.
Ratios:
For a deeper understanding of Eton Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 29.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 91.92. For the most recent quarter (mrq), Quick Ratio is recorded 1.43 and its Current Ratio is at 1.97. In the meantime, Its Debt-to-Equity ratio is 1.23 whereas as Long-Term Debt/Eq ratio is at 1.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 23, 2025, Reiterated its Buy rating but revised its target price to $33 from $17 previously.
On January 10, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $21.
H.C. Wainwright reiterated its Buy rating for the stock on January 06, 2025, while the target price for the stock was revised from $15 to $17.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 23 ’24 when Opaleye Management Inc. bought 10,000 shares for $7.98 per share. The transaction valued at 79,814 led to the insider holds 2,770,000 shares of the business.
Opaleye Management Inc. bought 33,970 shares of ETON for $238,782 on Oct 08 ’24. The 10% Owner now owns 2,760,000 shares after completing the transaction at $7.03 per share. On Oct 04 ’24, another insider, Opaleye Management Inc., who serves as the 10% Owner of the company, bought 16,852 shares for $6.77 each. As a result, the insider paid 114,105 and bolstered with 2,720,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 10.50 while its Price-to-Book (P/B) ratio in mrq is 20.75.
Stock Price History:
Over the past 52 weeks, ETON has reached a high of $21.48, while it has fallen to a 52-week low of $3.18. The 50-Day Moving Average of the stock is 20.35%, while the 200-Day Moving Average is calculated to be 58.62%.
Shares Statistics:
A total of 26.82M shares are outstanding, with a floating share count of 25.33M. Insiders hold about 5.53% of the company’s shares, while institutions hold 52.77% stake in the company.
Earnings Estimates
The market rating of Eton Pharmaceuticals Inc (ETON) is currently shaped by the ongoing analysis conducted by 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.13, with high estimates of $0.15 and low estimates of $0.1.
Analysts are recommending an EPS of between $0.56 and $0.3 for the fiscal current year, implying an average EPS of $0.45. EPS for the following year is $1.38, with 3.0 analysts recommending between $1.68 and $1.02.
Revenue Estimates
A total of 3 analysts believe the company’s revenue will be $16.29M this quarter.It ranges from a high estimate of $16.7M to a low estimate of $15.73M. As of the current estimate, Eton Pharmaceuticals Inc’s year-ago sales were $9.07MFor the next quarter, 3 analysts are estimating revenue of $19.31M. There is a high estimate of $20.6M for the next quarter, whereas the lowest estimate is $18.09M.
A total of 3 analysts have provided revenue estimates for ETON’s current fiscal year. The highest revenue estimate was $81.96M, while the lowest revenue estimate was $74.4M, resulting in an average revenue estimate of $77.72M. In the same quarter a year ago, actual revenue was $39.01MBased on 3 analysts’ estimates, the company’s revenue will be $117.61M in the next fiscal year. The high estimate is $123.54M and the low estimate is $107.4M.
